Compare Incyte Corporation (INCY) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Incyte Corporation trades at $120.65 (market cap $24.54B), while KraneShares Electric Vehicles and Future Mobility trades at $30.99. The key difference: Incyte Corporation is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| INCY | KARS | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $38.01 |
52-Week Low | $81.61 | $25.59 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
KARS trades at $30.99, down 0.42% on the day, with a bullish technical signal driven by moving averages and oscillators. The stock faces resistance near $31-$32, while support lies at $30-$29. Recent news highlights global EV sales growth, with China targeting 30% NEV fleet by 2030 and Europe seeing demand surges from high fuel prices, though U.S. adoption lags.
The outlook for KARS is supported by EV industry tailwinds, but risks include competitive pressures from Chinese automakers and regulatory delays. Analyst sentiment is mixed, with technical indicators suggesting near-term consolidation. Institutional interest may hinge on sustained EV adoption trends and execution against growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
